Shanton Pharma New Jersey Singapore

Shanton to Present Topline Data from Phase 2b Study with SAP-001 in Refractory Gout Patients at EULAR 2025 Congress

View original content:https://www.prnewswire.co.uk/news-releases/shanton-to-present-topline-data-from-phase-2b-study-with-sap-001-in-refractory-gout-patients-at-eular-2025-congress-302457828.html